Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
0 hedge funds and large institutions have $0 invested in Urovant Sciences Ltd. in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 41 closing their positions.
19.39% less ownership
Funds ownership: 19.39% → 0% (-19%)
100% less funds holding
Funds holding: 41 → 0 (-41)
100% less capital invested
Capital invested by funds: $102M → $0 (-$102M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 41
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$50.3M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$5.67M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.51M |
| 4 |
PCM
Prelude Capital Management
New York
|
-$3.99M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
-$3.89M |
UROV Hedge Fund Activity: Q1 2021 in Review
0 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q1 2021, worth a combined $0 — down 100% from $102M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of UROV and 0 opened new positions — a net loss of 41 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Perceptive Advisors, exiting entirely with an estimated $50.3M sold.
- 0 institutional investors held Urovant Sciences Ltd. (UROV) as of Q1 2021, down from 41 in Q4 2020.
- Funds reported $0 of Urovant Sciences Ltd. stock for Q1 2021, down 100% quarter-over-quarter.
- 0 funds opened new Urovant Sciences Ltd. positions in Q1 2021 and 41 closed out, a net change of -41 holders.
- The largest Urovant Sciences Ltd. seller in Q1 2021 was Perceptive Advisors, an estimated $50.3M sold.
Based on aggregated 13F filings for Q1 2021.